Post-transplant skin cancer: The influence of organ and pre-transplant disease

Cancer Treatment and Research

Volumn 146, Issue , 2009, Pages 65-74

  Euvrard, Sylvie ^a   Claudy, Alain ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

CANCER INCIDENCE; CANCER RISK; CLINICAL FEATURE; DISEASE COURSE; GEOGRAPHIC DISTRIBUTION; GRAFT RECIPIENT; GRAFT REJECTION; HEART GRAFT; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; KERATINOCYTE; KIDNEY FAILURE; KIDNEY GRAFT; LIVER FAILURE; LIVER GRAFT; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SKIN CANCER; TUMOR LOCALIZATION; COMORBIDITY; CYTOLOGY; HUMAN; PATHOLOGY; SARCOMA, KAPOSI; SKIN NEOPLASMS;

COMORBIDITY; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KERATINOCYTES; ORGAN TRANSPLANTATION; PROGNOSIS; SARCOMA, KAPOSI; SKIN NEOPLASMS;

EID: 77953656967     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-78574-5_6     Document Type: Review

References (61)

1. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348:1681-1691.
2. Bouwes-Bavinck JN, Hardie D, Green A, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. Transplantation 1996; 61:715-721.
3. Naldi L, Fortina AB, Lovati S, et al. Risk of nonmelanoma skin cancer in Italian organ transplant recipients. A registry-based study. Transplantation 2000; 70:1479.
4. Harden PN, Fryer AA, Reece S, et al. Annual incidence and predicted risk of nonmelanoma skin cancer in renal transplant recipients. Transplant Proc 2001; 33:1302-1304.
5. Ramsay HM, Fryer AA, Hawley CM, Smith AG, Nicol DL, Harden PN. Factors associated with nonmelanoma skin cancer following renal transplantation in Queensland, Australia. J Am Acad Dermatol 2003; 49:397-406.
6. Ulrich C, Schmook T, Sachse M, et al. Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients. Dermatol Surg 2004; 30:622-627.
7. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4:905-913.
8. Otley C, Cherikh WS, Salsche SJ, McBride MA, Christenson LJ, Kauffman HM. Skin cancer in organ transplant recipients: effect of pretransplant end-organ disease. J Am Acad Dermatol 2005; 53:783-790.
9. Kauffman HM, Cherikh WS, Cheng U, et al.Maintenance immunosuppression with target-ofrapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80:883-889.
10. Agraharkar ML, Cinclair RD, Kuo YF, Daller JA, Shahinian VB. Risk of malignancy with long-term immunosuppression in renal transplant recipients. Kidney Int 2004; 66:383-389.
11. Bordea C, Wojnarowska F, Millard PR, Doll H, Welsh K, Morris PJ. Skin cancers in renaltransplant recipients occur more frequently than previously recognized in a temperate climate. Transplantation 2004; 77:574-579.
12. Ramsay HM, Fryer AA, Hawley CM, Smith AG, Nicol DL, Harden PN. Non melanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol 2002; 147:950-956.
13. Fortina AB, Caforio AL, Piaserico S, et al. Skin cancer in heart transplant recipients: frequency and risk factor analysis. J Heart Lung Transplant 2000; 19:249-255.
14. Fuente MJ, Sabat M, Roca J, et al. A prospective study of the incidence of skin cancer and its risk factors in a Spanish Mediterranean population of kidney transplant recipients. Br J Dermatol 2003; 149; 1221-1226.
15. Espana A, Redondo P, Fernandez A, et al. Skin cancer in heart transplant recipients. J Am Acad Dermatol 1995; 32:458-465.
16. Ong CS, Keogh AM, Kossard S, Macdonald PS, Spratt PM. Skin cancer in Australian heart transplant recipients. J Am Acad Dermatol 1999; 40:27-34.
17. Lampros TD, Cobanoglu A, Parker F, et al. Squamous and basal cell carcinoma in heart transplant recipients. J Heart Lung Transplant 1998; 17:586-591.
18. Caforio AL, Fortina AB, Piaserico S, et al. Skin cancer in heart transplant recipients: risk factor analysis and relevance of immunosuppressive therapy. Circulation 2000; 102:222-227.
19. Euvrard S, Kanitakis J, Pouteil-Noble C, et al. Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. J Am Acad Dermatol 1995; 33:222-229.
20. Euvrard S, Kanitakis J, Decullier E, et al. Subsequent skin cancers in kidney and heart transplant recipients after the first squamous cell carcinoma. Transplantation 2006; 81:1093-1100.
21. Jensen P, Hansen S, Moller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999; 40:177-186.
22. Euvrard S, Kanitakis J. Skin cancers after liver transplantation: what to do? J Hepatol 2006; 44:27-32.
23. Mithoefer AB, Supran S, Freeman RB. Risk factors associated with the development of skin cancer after liver transplantation. Liver Transplant 2002; 8:939-944.
24. Herrero JI, Espana A, Quiroga J, et al. Nonmelanoma skin cancer after liver transplantation. Study of risk factors. Liver Transplant 2005; 11:1100-1106.
25. Jimenez-Romero C, Manrique Municio A, Marques Medina E, et al. Incidence of de novo nonmelanoma skin tumors after liver transplantation for alcoholic and non-alcoholic liver diseases. Transplant Proc 2006; 38:2505-2507.
26. Saigal S, Norris S,Muiesan P, et al. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation. Liver Transplant 2002; 8:482-487.
27. Jonas S, Rayes N, Neumann U, et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or CsA-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 1997; 80:1141-1150.
28. Haagsma EB, Hagens VE, Schaapveld M, et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol 2001; 34:84-91.
29. Farge D. Kaposi's sarcoma in organ transplant recipients. Eur J Med 1993; 2:339-343.
30. Serraino D, Angeletti C, Carrieri MP, et al. Kaposi's sarcoma in transplant and HIV-infected patients: an epidemiologic study in Italy and France. Transplantation 2005; 80:1699-1704.
31. Garcia-Astudillo LA, Levya-Cobian F. Human herpesvirus-8 infection and Kaposi's sarcoma after liver and kidney transplantation in different geographical areas of Spain. Transplant Immunol 2006; 17:65-69.
32. Becuwe C, Euvrard S, Bosshard S, et al. Kaposi's sarcoma and organ transplantation: 22 cases. Ann Dermatol Venereol 2005; 132:839-843.
33. Francés C, Lebbé C. Maladie de Kaposi du transplanté d'organe: faut-il prévenir, stabiliser ou guériř Ann Dermatol Vénéréol 2005; 132:829-831.
34. Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354:93-99.
35. Gruber SA, Gillingham K, Sothern RB, et al. De novo cancer in cyclosporine-treated and non cyclosporine-treated adult renal allograft recipients. Clin Transplant 1994; 8:388-395.
36. Danpanich E, Kasiske BL. Risk factors for cancer in renal transplant recipients. Transplantation 1999; 68:1859-1864.
37. Chapman JR, O'Connell PJ, Bovington KJ, Allen RD. Reversal of cyclosporine malabsorption in diabetic recipients of simultaneous pancreas and kidney transplant using a microemulsion formulation. Transplantation 1996; 61:1699-1704.
38. Van Duijnhoven E, Christiaans M, Schafer A, et al. Tacrolimus dosing requirements in diabetic and nondiabetic patients calculated from pretransplantation data. Transplant Proc 1998; 30:1266-1267.
39. Zanker B, Sohr B, Eder M, et al. Comparison of MPA trough levels in patients with severe diabetes mellitus and from non-diabetics after transplantation. Transplant Proc 1999; 31:1167.
40. Errasti P, Manrique J, Lavilla J, et al. Autosomal-dominant polycystic kidney disease: high prevalence of graft loss for death-related malignancies and cardiovascular risk factors. Transplant Proc 2003; 35:1717-1719.
41. Fitzpatrick PM, Torres VE, Charboneau JW, et al. Long-term outcome of renal transplantation in autosomal dominant polycystic kidney disease. Am J Kidney 1990; 15:535-543.
42. Johnston O, O'Kelly P, Donohue J, et al. Favorable graft survival in renal transplant recipients with polycystic kidney disease. Renal Fail 2005; 27:309-314.
43. Xiol X, Guardiola J, Menendez S, et al. Risk factors for development of de novo neoplasia after liver transplantation. Liver Transplant 2001; 7:971-975.
44. Benlloch S, Berenguer M, Prieto M, et al. De novo internal neoplasms after liver transplantation: increased risk and aggressive behavior in recent years? Am J Transplant 2004; 4:596-604.
45. Maffei F, Forti GC, Castelli E, Stefanini GF, Mattioli S, Hrelia P. Biomarkers to assess the genetic damage induced by alcohol abuse in human lymphocytes. Mutat Res 2002; 514:49-58.
46. Lindelhöf B, Dal H, Wolk K, Malmborg N. Cutaneous squamous cell carcinoma in organ transplant recipients. A study of the Swedish Cohort with regard to tumor site. Arch Dermatol 2005; 141:447-451.
47. Salard D, Parriaux N, Derancourt C, et al. Manifestations dermatologiques chez les transplant és hépatiques. Ann Dermatol Venereol 2002; 129:1134-1138.
48. Perera GK, Child FJ, Heaton N, et al. Skin lesions in adult liver transplant recipients: a study of 100 consecutive patients. Br J Dermatol 2006; 154:868-872.
49. Romero-Vargas ME, Flores-Cortes M, Valera Z, et al. Cancers of new appearance in liver transplant recipients: incidence and evolution. Transplant Proc 2006; 38:2508-2510.
50. Aseni P, Vertemati M, De Carlis L, et al. De novo cancers and post-transplant lymphoproliferative disorder in adult liver transplantation. Pathol Int 2006; 56:712-715.
51. Adamson R, Obispo E, Dychter S, et al. High incidence and clinical course of aggressive skin cancer in heart transplant patients: a single-center study. Transplant Proc 1998; 30:1124-1126.
52. Veness MJ, Quinn DI, Ong CS, et al. Aggressive cutaneous malignancies following cardiothoracic transplantation. Cancer 1999; 85:1759-1764.
53. Colina F, Lopez-Rios F, Lumbreras C, et al. Kaposi's sarcoma developing in a liver graft. Transplantation 1996; 61:1779-1781.
54. Aseni P, Vertemati M, Minola E, et al. Kaposi's sarcoma in liver transplant recipients: morphological and clinical description. Liver Transplant 2001; 7:816-823.
55. Marcellin AG, Roque-Afonso AM, HurtovaM, et al. Fatal disseminated Kaposi's sarcoma following human herpesvirus 8 primary infections in liver transplant recipients. Liver Transplant 2004; 10:295-300.
56. Woodle ES, Hanaway M, Buell J, et al. Kaposi's sarcoma: an analysis of the US and international experiences from the Israel Penn International Transplant Registry. Transplant Proc 2001; 33:3360-3361.
57. Otley CC,Maragh SL. Reduction of immunosuppression for transplant-associated skin cancer: rationale and evidence of efficacy. Dermatol Surg 2005; 31:163-168.
58. Tessmer CS, Magalhaes LV, Keitel E, et al. Conversion to sirolimus in renal transplant recipients with skin cancer. Transplantation 2006; 82:1792-1793.
59. Fernandez A, Marcen R, Pascual J, et al. Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia. Transplant Proc 2006; 38:2453-2455.
60. Ismail F, Mitchell L, Casabonne D, et al. Specialist dermatology clinics for organ transplant recipients significantly improve photoprotection and levels of skin cancer awareness. Br J Dermatol 2006; 155:916-925.
61. Clowers-Webb HE, Christenson LJ, Phillips PK, et al. Educational outcomes regarding skin cancer in organ transplant recipients: randomized intervention of intensive vs. standard education. Arch Dermatol 2006; 142:712-718.